Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART: A Phase I/II, Double-blind, Placebo-controlled, Ascending Multiple Dose Study
Latest Information Update: 11 Apr 2022
At a glance
- Drugs Cemiplimab (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- 16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections
- 11 Nov 2021 Status changed from completed to discontinued.
- 08 Sep 2020 Status changed from active, no longer recruiting to completed.